Products for Research Use Only

ELND 007

CAT: 0804-HY-16633Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-16633Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ELND 007 (Compound 34) is a metabolically stable γ-secretase inhibitor designed to selectively inhibit amyloid beta (Aβ) generation while minimizing Notch inhibition. Developed alongside ELND 006 (Compound 30), it underwent human clinical trials following a synthetic strategy emphasizing diversity and chirality. In preclinical studies, ELND 007 showed promising in vitro and in vivo characteristics, effectively reducing Aβ levels. Comparative studies with other γ-secretase inhibitors like Semagacestat, Begacestat, and Avagacestat highlighted its efficacy in lowering Aβ production, particularly demonstrated by reduced Aβ levels in the cerebrospinal fluid (CSF) of healthy human volunteers, suggesting potential therapeutic benefit for Alzheimer's disease[1].
CAS Number
1444006-79-4
UNSPSC
12352005
Target
Amyloid-β; γ-secretase
Type
Reference compound
Related Pathways
Neuronal Signaling; Stem Cell/Wnt
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/elnd-007.html
Smiles
O=S(N1[C@H](C2CC2)C3=CNN=C3C4=C1C=CC(F)=C4)(C5=CC=C(C(F)(F)F)N=C5)=O
Molecular Formula
C19H14F4N4O2S
Molecular Weight
438.40
References & Citations
[1]Discovery of (R) -4-Cyclopropyl-7,8-difluoro-5- (4- (trifluoromethyl) phenylsulfonyl) -4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R) -4-Cyclopropyl-8-fluoro-5- (6- (trifluoromethyl) pyridin-3-ylsulfonyl) -4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007) : Metabolically Stable γ-Secretase Inhibitors that Selectively Inhibit the Production of Amyloid-β over Notch
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported